ABSTRACT
Monoclonal antibodies (MAbs) are currently developed by pharmaceutical and biotechnology companies for various therapeutic applications. MAbs undergo several post-translational modifications including oxidations, deamidations, lysine truncations, and glycan modifications. Manufacturing of MAbs and subsequent stability testing procedures involve routine analysis and monitoring of the impurities resulting from asparagine deamidation, aspartic acid isomerization, disulfide interchange, peptide bond cleavage, and oxidation. ProPac® WCX and ProSwift™ WCX columns are widely used to characterize MAb heterogeneity.
